Ποια είναι η τιμή για Affimed N.V. (AFMD)

Η τιμή για Affimed N.V. (AFMD) είναι $0.1815

Ποια είναι η κεφαλαιοποίηση αγοράς για Affimed N.V. (AFMD)

Η κεφαλαιοποίηση αγοράς για Affimed N.V. (AFMD) είναι $2.78M

Affimed N.V. (AFMD) Τιμή και Κεφαλαιοποίηση Αγοράς

Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma. Beyond AFM13, Affimed is actively developing several other therapeutic candidates. These include AFM24, a distinctive tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptor (EGFR) and CD16A; it is presently undergoing Phase IIa clinical trials for a range of advanced cancers. Further back in the pipeline are AFM28, an innate cell engager (ICE) in preclinical development for acute myeloid leukemia, and AFM32, another ICE candidate also in preclinical stages, aimed at solid tumors. The company has forged strategic collaboration agreements with prominent institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. Moreover, it benefits from a research funding agreement with The Leukemia & Lymphoma Society. Founded in 2000 and headquartered in Heidelberg, Germany, the organization transitioned its name to Affimed N.V. in October 2014, having previously operated as Affimed Therapeutics B.V.

Η τιμή για AFMD	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$356,297 $2.78M	NVDA	$5.452T	+196,306,557.93%
$293,437 $2.78M	AAPL	$4.490T	+161,673,091.02%
$272,026 $2.78M	GOOG	$4.162T	+149,876,648.81%
$240,260 $2.78M	MSFT	$3.676T	+132,374,809.48%
$185,148 $2.78M	AMZN	$2.833T	+102,009,918.74%

Η τιμή για AFMD

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$356,297 $2.78M